Hot Features
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in t... Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.26 | -17.5675675676 | 1.48 | 1.48 | 1.08 | 270632 | 1.27282061 | DR |
| 4 | -0.29 | -19.2052980132 | 1.51 | 1.85 | 1.08 | 283777 | 1.42636504 | DR |
| 12 | -0.05 | -3.93700787402 | 1.27 | 1.85 | 1.08 | 203123 | 1.34923414 | DR |
| 26 | -0.52 | -29.8850574713 | 1.74 | 1.85 | 1.08 | 230906 | 1.46976439 | DR |
| 52 | -0.23 | -15.8620689655 | 1.45 | 2.6 | 1.08 | 283546 | 1.733831 | DR |
| 156 | -0.01 | -0.813008130081 | 1.23 | 2.6 | 0.41 | 326814 | 1.20346892 | DR |
| 260 | -1.14 | -48.3050847458 | 2.36 | 2.84 | 0.41 | 273081 | 1.27902034 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.